Table 4.
Gene sets correlated with symptom severity.
| Gene set | Library | P-value | # | Genes |
|---|---|---|---|---|
| PANSS Positive symptom correlated pathways | ||||
| Measles | KEGG | 0.0034 | 8 | CD3E, CD46, FYN, IFNGR1, IL1B, IL2RB, IRF3, TBK1 |
| Cytokine production | GOBP | 0.009 | 6 | CASP1, CD46, EOMES, IL1B, PTGS2, TBK1 |
| Regulation of NF-kB signalling | GOBP | 0.0168 | 8 | CASP1, CXXC5, FYN, IL1B, IRF3, PELI1, PTGS2, TBK1 |
| Red Blood Cell | Blood | 0.0199 | 18 | BAZ2B, CD46, CKLF, COX7A2, DYNLT1, GALC, GNG10, IFNGR1, LYST, PELI1, PTGS2, RAB5A, RNF13, SHOC2, SRGN, TBK1, TNFAIP6, TXN |
| Ras signalling | KEGG | 0.0219 | 9 | CSF1R, GNG10, LAT, RAB5A, RASAL3, RASGRP2, SHOC2, TBK1, ZAP70 |
| Cytosol | GOCC | 0.035 | 31 | ALDOC, CAPZA2, CASP1, DPYD, FASN, FYN, IDH1, IL1B, IRF3, ITPKB, LYST, MATK, OSBPL7, PDE7A, PELI1, PTEN, RAP2C, TBK1, TXN, UBE2E1, USP7 |
| PANSS Negative symptom correlated pathways | ||||
| Viral transcription | GOBP | <0.001 | 8 | RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6 |
| Cytosolic part | GOCC | <0.001 | 9 | AHR, RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6 |
| Ribosome | GOMF | <0.001 | 8 | RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6 |
| Ribosome | KEGG | <0.001 | 8 | RPL11, RPL21, RPL35, RPL4, RPL5, RPS3, RPS5, RPS6 |
| Mitochondria | Brain | 0.0071 | 6 | COX6C, NDUFS5, PPA2, RPL11, RPL4, RPL5 |
Table of gene sets enriched with DE genes significantly correlated to positive or negative symptoms in FEP. The 120 and 37 DE genes significantly correlated, respectively, with Positive and Negative symptoms were used for gene enrichment analysis. Significant pathways are shown separately for the two symptom dimensions. P-values are Bonferroni corrected. Total number of DE genes overlapping with gene sets are indicated in the # column. For complete results, including genes correlated with symptom severity, see supplementary table 4.
Table of gene sets enriched with DE genes significantly correlated to positive or negative symptoms in FEP. The 120 and 37 DE genes significantly correlated, respectively, with Positive and Negative symptoms were used for gene enrichment analysis. Significant pathways are shown separately for the two symptom dimensions. P-values are Bonferroni corrected. Total number of DE genes overlapping with gene sets are indicated in the # column. For complete results, including genes correlated with symptom severity, see supplementary table 4.